• Edwards Lifesciences disclosed 10-year results from its COMMENCE aortic trial, already presented at 106th American Association for Thoracic Surgery Annual Meeting.
• Study showed RESILIA tissue valves maintained durability over a decade, supporting long-term performance in surgical aortic valve replacement.
• Findings point to lower likelihood of repeat procedures over patients’ lifetimes, including in younger cohorts where valve wear has been a bigger concern.
• Update strengthens Edwards’ positioning in tissue-valve durability as clinicians consider earlier intervention in aortic stenosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202605021150BIZWIRE_USPR_____20260502_BW326120) on May 02, 2026, and is solely responsible for the information contained therein.